Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
Background Neuroblastoma (NB) is a childhood cancer for which new treatment options are needed. The success of immune checkpoint blockade in the treatment of adult solid tumors has prompted the exploration of immunotherapy in NB; however, clinical evidence indicates that the vast majority of NB pati...
Saved in:
| Main Authors: | Marjan Rafat, Justin M. Balko, Lihong Wang-Bishop, Mohamed Wehbe, Daniel Shae, Jamaal James, Benjamin C. Hacker, Kyle Garland, Plamen P. Chistov, John T. Wilson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000282.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanomedicine based on chemotherapy-induced immunogenic death combined with immunotherapy to enhance antitumor immunity
by: Yichang Chen, et al.
Published: (2024-12-01) -
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
by: Lei Huang, et al.
Published: (2020-10-01) -
Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
by: Xiyuan Wang, et al.
Published: (2025-01-01) -
Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research
by: Yifei Liu, et al.
Published: (2024-12-01) -
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch
by: Judith Wienke, et al.
Published: (2022-12-01)